Petrus Trust Company’s Corcept Therapeutics CORT Stock Holding History

Petrus Trust Company’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,981	Closed	-$251K	–	624
2024 Q4	$251K	Buy	+4,981	New	+$261K	0.02%	493
2024 Q3	–	Sell	-21,151	Closed	-$687K	–	583
2024 Q2	$687K	Sell	21,151 -9,270	-30%	-$254K	0.06%	110
2024 Q1	$766K	Sell	30,421 -7,789	-20%	-$184K	0.07%	77
2023 Q4	$1.24M	Buy	38,210 +13,323	+54%	+$366K	0.12%	27
2023 Q3	$678K	Buy	24,887 +4,704	+23%	+$136K	0.07%	93
2023 Q2	$449K	Hold	20,183	–	–	0.05%	192
2023 Q1	$437K	Sell	20,183 -3,940	-16%	-$86.4K	0.05%	136
2022 Q4	$490K	Buy	+24,123	New	+$605K	0.06%	99
2020 Q3	–	Sell	-10,807	Closed	-$182K	–	287
2020 Q2	$182K	Hold	10,807	–	–	0.02%	202
2020 Q1	$128K	Buy	+10,807	New	+$134K	0.02%	140
2018 Q1	–	Sell	-16,359	Closed	-$295K	–	175
2017 Q4	$295K	Buy	+16,359	New	+$296K	0.07%	102
2015 Q3	–	Sell	-23,901	Closed	-$144K	–	138
2015 Q2	$144K	Buy	+23,901	New	+$147K	0.03%	82

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Petrus Trust Company's CORT Position: Q1 2025 in Review

Petrus Trust Company sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 4,981 shares — an estimated $251K sold.

Petrus Trust Company first reported a position in CORT in Q2 2015 and held it in 12 quarters. The position peaked at $1.24M in Q4 2023. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

Petrus Trust Company reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
Petrus Trust Company sold 4,981 Corcept Therapeutics shares in Q1 2025, an estimated $251K.
Petrus Trust Company first reported a position in Corcept Therapeutics in Q2 2015 and held it in 12 quarters.
Petrus Trust Company's Corcept Therapeutics position peaked at $1.24M in Q4 2023.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Petrus Trust Company's 13F filing for Q1 2025, filed 15 May 2025.